MedTrace Logo

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

NCT01714817 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 695

Last updated 2021-02-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate (Abatacept) for treatment of lupus nephritis when used on a background of Cellcept (mycophenolate) and prednisone (corticosteroids)

Conditions

Interventions

BIOLOGICAL

BMS-188667

DRUG

Mycophenolate mofetil

DRUG

Prednisone

BIOLOGICAL

Placebo matching with BMS-188667

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-22
Primary Completion
2016-11-21
Completion
2018-05-30

Countries

  • United States
  • Argentina
  • Australia
  • Brazil
  • Canada
  • Chile
  • China
  • Colombia
  • Czechia
  • Hong Kong
  • India
  • Israel
  • Italy
  • Japan
  • Mexico
  • Peru
  • Puerto Rico
  • Romania
  • Russia
  • South Korea
  • Spain
  • Taiwan
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01714817 on ClinicalTrials.gov